Literature DB >> 25616158

Genomic discoveries in adult astrocytoma.

Joanna Wang1, Chetan Bettegowda2.   

Abstract

Astrocytomas are the most common glial tumor of the central nervous system. Within this category, glioblastoma is the most prevalent and malignant primary brain tumor. Glioblastoma can arise de novo, or through progression from lower-grade lesions, but is uniformly associated with poor outcomes despite surgical resection, chemotherapy, and radiation therapy. Recent genomic discoveries have provided new insight into gliomagenesis and have identified key genetic alterations that have diagnostic, prognostic and predictive capacity. Numerous molecular classification schemes have been proposed to sort tumors into clinically meaningful categories to guide treatment. However, creating therapy targeted towards these alterations has been made challenging by the redundancy of essential signal transduction pathways affected in these tumors, intratumoral heterogeneity, and the hypermutated profiles of recurrent tumors. Future treatment strategies will require a personalized approach with consideration of the unique genetic profile of a specific tumor and the use of multimodality therapies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25616158      PMCID: PMC4859210          DOI: 10.1016/j.gde.2014.12.002

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  66 in total

1.  Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas.

Authors:  Nicolas Vogt; Sandrine-Hélène Lefèvre; Françoise Apiou; Anne-Marie Dutrillaux; Andrej Cör; Pascal Leuraud; Marie-France Poupon; Bernard Dutrillaux; Michelle Debatisse; Bernard Malfoy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-21       Impact factor: 11.205

2.  Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells.

Authors:  Qihui Shi; Lidong Qin; Wei Wei; Feng Geng; Rong Fan; Young Shik Shin; Deliang Guo; Leroy Hood; Paul S Mischel; James R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

3.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

4.  A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

Authors:  Brian Thiessen; Clinton Stewart; Ming Tsao; Suzanne Kamel-Reid; Paula Schaiquevich; Warren Mason; Jacob Easaw; Karl Belanger; Peter Forsyth; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Cancer Chemother Pharmacol       Date:  2010-01       Impact factor: 3.333

5.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

6.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

7.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

Review 8.  Next-generation molecular genetics of brain tumours.

Authors:  Mario L Suvà; David N Louis
Journal:  Curr Opin Neurol       Date:  2013-12       Impact factor: 5.710

9.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  5 in total

1.  Delayed cerebral pseudoaneurysm following surgical and combined-modality therapy for glioblastoma multiforme: illustrative case.

Authors:  Hari N Krishnakumar; Colin Son
Journal:  J Neurosurg Case Lessons       Date:  2022-07-11

2.  Expression Profile of MiR-128 in the Astrocytoma Patients and Cell Lines.

Authors:  Jingjing Xu; Yuqiong Liu; Si Guo; Shengli Ma; Lin Xiao; Na Wei; Rui Xue
Journal:  Mol Neurobiol       Date:  2015-08-26       Impact factor: 5.590

3.  Nuclear receptor NR5A2 negatively regulates cell proliferation and tumor growth in nervous system malignancies.

Authors:  Dimitrios Gkikas; Dimitris Stellas; Alexia Polissidis; Theodora Manolakou; Maroula G Kokotou; George Kokotos; Panagiotis K Politis
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-28       Impact factor: 11.205

4.  Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM.

Authors:  Luca Pasquini; Antonio Napolitano; Emanuela Tagliente; Francesco Dellepiane; Martina Lucignani; Antonello Vidiri; Giulio Ranazzi; Antonella Stoppacciaro; Giulia Moltoni; Matteo Nicolai; Andrea Romano; Alberto Di Napoli; Alessandro Bozzao
Journal:  J Pers Med       Date:  2021-04-09

5.  AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well?

Authors:  Luca Pasquini; Antonio Napolitano; Martina Lucignani; Emanuela Tagliente; Francesco Dellepiane; Maria Camilla Rossi-Espagnet; Matteo Ritrovato; Antonello Vidiri; Veronica Villani; Giulio Ranazzi; Antonella Stoppacciaro; Andrea Romano; Alberto Di Napoli; Alessandro Bozzao
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.